The Dupilumab studies as reported in the New England Journal of Medicine and the Journal of the American Academy of Dermatology and by me on discussed in my four prior posts exhibit multiple violations in the study of new drugs and scientific reporting. Inclusion of patients: from my experience with 4000 totally similar patients none [...]
In recounting the diagnosis, management and cure of 4000 corticosteroid addicted atopic dermatitis patients I feel like I am in a futuristic movie with a split screen simultaneously showing two similar populations. One population is now in the present consisting of suffering patients who go on to CURE – albeit through a prolonged period of [...]
Dupilumab is now FDA approved as of March 28, 2017 and this event necessitates a further evaluation for the prospects of this drug helping eczema patients. Physicians and patients are being told the published results but they deserve an objective critique. There are multiple discrepancies and violations of true, honest research and in looking at [...]
After having cured 4000 plus patients with steroid addiction and Red Skin Syndrome, I feel duty bound to offer sound advice to those still mismanaged suffering patients still floundering in their care. In that regard I look at every new drug offering promise of improvement or cure to these patients. I dissect the quality of [...]
The following are comments by Marvin Rapaport MD, owner of this website, Red Skin Syndrome, and edited and clearly written by an esteemed writer and journalist, Ruchy Reese, who writes for the monthly magazine, Wellspring. I am writing in response to an article that appeared in the December 15, 2016 edition of the New [...]
Dr. Rapaport, I recently came across one of the pictures of my Topical Steroid Withdrawal/Red Skin Syndrome (TSW/RSS) journey. It was of my lips – swollen, red, burning, peeling, splitting. Some symptoms were apparent before stopping TS, yet several dermatologists continued to prescribe them, Protopic and Elidel. I also endured probably all of the other [...]
